STEM CELL MODELS TO UNRAVEL THE SUSCEPTIBILITY AND RESILIENCE TO DEVELOP HEART FAILURE
| Title | STEM CELL MODELS TO UNRAVEL THE SUSCEPTIBILITY AND RESILIENCE TO DEVELOP HEART FAILURE |
|---|---|
| Acronym | STOP-HF |
| Website | https://www.groningencardiology.com/ |
| Start date | 2017-03-01 |
| End date | 2022-03-01 |
| Sponsor | European Research Council - Starting Grant (ERC-StG) |
| Institution | University Medical Center Groningen |
Associated cell lines
- UMCGi001-A (PPCM RC1 c1)
- UMCGi001-B (PPCM RC1 c2)
- UMCGi002-A (CTP1-C1)
- UMCGi002-B (CTP1-C2)
- UMCGi002-C (CTP1-C3)
- UMCGi003-A (PPCM RP1 c1)
- UMCGi003-B (PPCM RP1 c3)
- UMCGi004-A (PPCM RC2 c1)
- UMCGi004-B (PPCM RC2 c2)
- UMCGi005-A (PPCM RP2 c2)
- UMCGi005-B (PPCM RP2 c9)
- UMCGi006-A (DRP1-C2)
- UMCGi006-B (DRP1-C3)
- UMCGi007-A (DRP2-C2)
- UMCGi007-B (DRP2-C4)
- UMCGi008-A (DRP3-C5)
- UMCGi008-B (DRP3-C7)
- UMCGi008-C (DRP3-C10)
- UMCGi008-D (DRP3-C11)
- UMCGi011-A (CTP2)
- UMCGi011-B (CTP2-C5)
- UMCGi011-C (CTP2-C4)
Project Description
The overarching objective of STOP-HF is to generate human induced pluripotent stem cells (hiPSC) derived cardiomyocytes from two specific forms of heart failure (HF) with a clear trigger to unravel common pathophysiological mechanisms involved in the early development of HF. The project is focused on two specific forms of HF, both with a clear trigger: pregnancy and anthracyclines. Better understanding of early molecular pathways leading to HF and knowledge about inter-individual susceptibility is needed. For detection of early changes on a molecular level cardiac tissue is needed. Generation of patient specific cardiac cells from skin fibroblasts (hiPSC technology) is a novel and innovative approach. SPECIFIC OBJECTIVES 1. Fabrication and maturation of 3D cardiac tissue from hiPS derived cardiomyocytes. 2. Generate and characterize hiPS derived cardiomyocytes and endothelial cells from females with pregnancy induced HF and unravel differences on transcriptome level. 3. Generate and characterize hiPSC derived cardiomyocytes from patients with high susceptibility and resilience to develop anthracycline-induced HF and compare them on transcriptome level. 4. Integrate the results for coding and non-coding RNAs from objective 1+2 and identify overlapping pathways. 5. Validate discoveries on transcriptome level in vitro, in vivo and apply for the development of HF in the general population.